<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02228850</url>
  </required_header>
  <id_info>
    <org_study_id>NexMed 2014-RPS-001</org_study_id>
    <nct_id>NCT02228850</nct_id>
  </id_info>
  <brief_title>Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis</brief_title>
  <official_title>A Phase 2a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of the Acute Peripheral Vascular Effects, Safety and Tolerability of Alprostadil Topical Cream in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis (SSc, Scleroderma)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate pharmacodynamics (PD) in adult subjects with a&#xD;
      diagnosis of Raynaud's Phenomenon secondary to Systemic Sclerosis (SSc).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the pharmacodynamic (PD) effects of topical&#xD;
      Alprostadil on digital perfusion by laser Doppler capillary velocimetry and digital&#xD;
      temperature recovery with thermography following standardized cold challenge and to assess&#xD;
      the safety and tolerability of 3 doses of Alprostadil topical cream and placebo cream in&#xD;
      adult subjects with a diagnosis of Raynaud's Phenomenon secondary to Systemic Sclerosis&#xD;
      (SSc).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacodynamic evaluation: digital perfusion by laser Doppler capillary velocimetry and on digital temperature recovery with thermography.</measure>
    <time_frame>two hours (intermittently) after cold-challenge and post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessments based on review of adverse events, vital sign measurements, electrocardiograms, physical examinations, and clinical laboratory tests.</measure>
    <time_frame>One month</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Raynaud's Phenomenon Secondary to Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>Alprostadil Cream (300mcg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 micrograms/.42% Alprostadil Cream with 2.5% Dodecyl-2-N,N-dimethylaminopropionate hydrochloride (DDAIP-HCl) and Placebo, one dispenser for each administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alprostadil Cream (1000mcg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000 micrograms/.42% Alprostadil Cream with 2.5% Dodecyl-2-N,N-dimethylaminopropionate hydrochloride (DDAIP-HCl) and Placebo, one dispenser for each administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alprostadil Cream (3000mcg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3000 micrograms/.42% Alprostadil Cream with 2.5% Dodecyl-2-N,N-dimethylaminopropionate hydrochloride (DDAIP-HCl) and Placebo, two dispensers for each administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alprostadil</intervention_name>
    <arm_group_label>Alprostadil Cream (1000mcg)</arm_group_label>
    <arm_group_label>Alprostadil Cream (3000mcg)</arm_group_label>
    <arm_group_label>Alprostadil Cream (300mcg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Alprostadil Cream (1000mcg)</arm_group_label>
    <arm_group_label>Alprostadil Cream (3000mcg)</arm_group_label>
    <arm_group_label>Alprostadil Cream (300mcg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with a diagnosis of SSc by current ACR/EULAR Classification Criteria;&#xD;
&#xD;
          -  Evidence of ongoing activity of Raynaud's Phenomenon as measured by a Raynaud&#xD;
             Condition Score of 3 or greater at Screening;&#xD;
&#xD;
          -  All females of childbearing potential must have a negative serum pregnancy test;&#xD;
&#xD;
             a. Females of childbearing potential must abstain from sexual activity that could&#xD;
             result in pregnancy, or agree to use an acceptable method of contraception throughout&#xD;
             the study period and for 30 days following dosing of the investigational study drug.&#xD;
             Acceptable contraception includes:&#xD;
&#xD;
               1. Intrauterine devices&#xD;
&#xD;
               2. Double barrier methods (e.g. condom or diaphragms with spermicidal gel or foam)&#xD;
&#xD;
               3. Condom use is advised for all forms of contraception&#xD;
&#xD;
          -  Must be willing and able to discontinue ongoing therapy for RP for at least 72 hours&#xD;
             prior to each application of study medication; such drugs include calcium channel&#xD;
             blockers, angiotensin-converting enzyme (ACE) inhibitors, short-acting PDE-5i&#xD;
             (sildenafil, vardenafil, avanafil), sympatholytics and topical or systemic nitrates;&#xD;
&#xD;
          -  Must be willing and able to discontinue consumption of caffeine-containing products&#xD;
             (e.g., beverages and over-the-counter (OTC) medications) for at least 24 hours prior&#xD;
             to each day of study dosing;&#xD;
&#xD;
          -  Must be willing and able to remove jewelry from the treated hand prior to each day of&#xD;
             study dosing;&#xD;
&#xD;
          -  Must be willing to remove nail polish and/or nail coverings from the treated hand&#xD;
             prior to each day of study dosing;&#xD;
&#xD;
          -  Must not donate blood during the study;&#xD;
&#xD;
          -  Have adequate finger extension to permit application of study treatments and&#xD;
             attachment of physiologic measuring instruments.&#xD;
&#xD;
          -  Must be willing to comply with all study procedures and study visits;&#xD;
&#xD;
          -  Must provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BMI less than 18.5;&#xD;
&#xD;
          -  Clinically significant medical abnormality or history or presence of significant&#xD;
             neurological, hepatic, renal, endocrine, gastrointestinal, cardiovascular, pulmonary,&#xD;
             psychiatric and/or metabolic condition as determined by the Investigator);&#xD;
&#xD;
          -  Clinical diagnosis of Systemic Sclerosis in association with other rheumatologic&#xD;
             diseases including Mixed Connective Tissue Disease;&#xD;
&#xD;
          -  Clinically significant abnormal laboratory test results at screening as determined by&#xD;
             the Investigator;&#xD;
&#xD;
          -  Raynaud's Phenomenon thought to be of non-systemic sclerosis etiology;&#xD;
&#xD;
          -  Peripheral or central vasculopathy other than Systemic Sclerosis;&#xD;
&#xD;
          -  History of Scleroderma renal crisis or currently being treated for hypertension,&#xD;
             however, subjects with controlled hypertension will not be excluded;&#xD;
&#xD;
          -  Active digital ulcers or rash on hand intended for study medication;&#xD;
&#xD;
          -  History in the past (5) five years of autonomic neuropathy or postural hypotension;&#xD;
&#xD;
          -  Upper extremity sympathectomy at any level in the 12 months prior to study;&#xD;
&#xD;
          -  Tobacco smoking within six months of screening or unwillingness to avoid smoking&#xD;
             throughout the study (e.g., cigarette, pipe, cigar, e-cigarettes) and the use of&#xD;
             nicotine-containing products;&#xD;
&#xD;
          -  Systolic Blood pressure less than 85mm/Hg;&#xD;
&#xD;
          -  Prostanoid use by any route of administration within the previous six months;&#xD;
&#xD;
          -  Current use of systemic or topical nitrates, endothelin receptor antagonists (e.g.,&#xD;
             bosentan) or any long-acting PDE-5 Inhibitors (e.g. tadalafil);&#xD;
&#xD;
          -  Use of topical corticosteroid to the hand or fingers within 10 days of screening;&#xD;
&#xD;
          -  Current use of ergot preparations, methysergide, B-adrenergic antagonists,&#xD;
             contraceptives containing female steroid hormones, cyclosporine, clonidine, nicotine&#xD;
             and cocaine;&#xD;
&#xD;
          -  Pregnant or lactating female;&#xD;
&#xD;
          -  Has known exaggerated pharmacological sensitivity or hypersensitivity to any drug&#xD;
             similar to Alprostadil or its excipients;&#xD;
&#xD;
          -  Has known hypersensitivity to nitrile;&#xD;
&#xD;
          -  Involvement in any investigational drug or device study within 30 days prior to&#xD;
             screening;&#xD;
&#xD;
          -  History of non-compliance with treatment or clinic visit attendance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Troupin, MD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>NEXMED (U.S.A.), Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diagnamics, Inc.</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Scleroderma Program - Division of Rheumatology/Dept. of Internal Medicine</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scleroderma Research Center - University of Pittsburgh School of Medicine</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>August 20, 2014</study_first_submitted>
  <study_first_submitted_qc>August 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2014</study_first_posted>
  <last_update_submitted>March 21, 2016</last_update_submitted>
  <last_update_submitted_qc>March 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Secondary Raynaud's Phenomenon</keyword>
  <keyword>Secondary Raynaud's Disease</keyword>
  <keyword>Scleroderma</keyword>
  <keyword>Raynaud's Disease secondary to systemic sclerosis</keyword>
  <keyword>CREST</keyword>
  <keyword>Apricus Biosciences</keyword>
  <keyword>laser doppler</keyword>
  <keyword>thermography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Raynaud Disease</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alprostadil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

